Archangels’ half-year investment figures landed last week, and while the headline number — £17.9m of investment leveraged into Scottish scale-ups in the first six months of 2026 — will find its natural home on the financial pages, a couple of the underlying features seem worth noting for anyone who watches Scottish deep-tech capital flows closely.
The number itself is straightforward enough. Archangels’ members put in £7.2m directly, and £10.7m arrived alongside from partner co-investors. The half-year pace, if broadly sustained, tracks the run-rate that took the syndicate to a record £41.1m in 2025 — itself around 50 per cent above 2024’s £27.3m. Two consecutive years running well ahead of the syndicate’s historic £13–15m annual norm may or may not turn into a settled trend, but it does start to look like more than a single strong year.
A few features of the H1 book are, at least, interesting.
The first is the co-investment ratio. Roughly 60 per cent of the £17.9m came from co-investors rather than from Archangels’ own members. That is a noticeably higher ratio than the syndicate ran a decade ago, and readers who follow this closely will already have observed the broader shift: Scottish angel capital, over the past few years, has increasingly acted as the assembly point around which larger rounds are put together, rather than the whole cheque. The H1 figures seem consistent with that pattern continuing.
The second is that Edinburgh’s translational cluster does most of the visible work in the H1 disclosures. All three named 2026 Archangels transactions — Bioliberty, Biocaptiva and Bead BioPharma — are Edinburgh-originated life-sciences or medtech-with-AI companies, with Edinburgh Innovations, the University of Edinburgh’s commercialisation office, showing up as a shared thread. Whether that concentration reflects the shape of Scotland’s investable deep-tech pipeline more generally, or the shape of Archangels’ own particular investment preferences, is a question that probably has some of both in the answer.
The third feature — and, on our reading, perhaps the most interesting one — is the Scottish National Investment Bank’s role in the Bioliberty Series A. SNIB led that round with a £3m commitment out of £6.2m raised. That’s a lead-investor role, in a Scottish deep-tech Series A of a scale that in earlier years would almost certainly have needed an outside lead. Silicon readers with a longer memory will recall that SNIB’s early public reputation was often characterised, fairly or otherwise, as a passive co-investor; the H1 book adds one more data point to a growing set that suggests a different posture may be settling in.
Put the three features together and one might reasonably observe that Scotland’s early-stage deep-tech capital stack — origination through Edinburgh Innovations or equivalent, seed anchored by Archangels, Series A led by SNIB, and international co-investment filled in by partners such as Conduit Connect, Hanna Capital SEZC, Eos Advisory and Old College Capital — appears to be taking on a more joined-up shape than it had a few years ago. Whether that’s a durable structural change or a favourable moment in the cycle is genuinely open to argument.
Two things seem worth flagging as caveats.
The first is that the visible strength is at seed and Series A. Once a Scottish deep-tech company outgrows that stage, the local lead-investor bench has historically thinned quickly, and Series B has often meant a London, Boston or San Francisco round. Nothing in the H1 disclosures speaks to that particular constraint, and it remains — on the current shape of Scotland’s institutional capital base — an open question.
The second is concentration. Two of the three named 2026 deals are University of Edinburgh spin-outs in life-sciences-adjacent territory, which is a real cluster strength but also a real cluster narrowness. Glasgow’s photonics and quantum cluster, Dundee’s gaming and computational biology base, and Aberdeen’s energy-tech transition companies aren’t visible in this particular dataset, and readers who watch those sub-clusters will have a better sense than we do of how their 2026 has looked.
None of this changes the fact that Archangels having leveraged £17.9m of investment into Scottish scale-ups by the end of June is a good number in a market that has, elsewhere in the UK, felt materially harder. It’s more that the composition of the number — the co-investment ratio, the Edinburgh concentration, the SNIB lead role — arguably tells the more interesting story about where Scotland’s early-stage capital infrastructure is heading.
Silicon will look at Bioliberty in more detail on Monday, and at Biocaptiva later next week.
